J Rheum Dis.  2025 Jan;32(1):3-7. 10.4078/jrd.2024.0072.

Assessment of disease activity and quality of life of Korean patients with rheumatoid arthritis

• Lee YH
• Jun JB

• KMID: 2562654
• DOI: http://doi.org/10.4078/jrd.2024.0072

Abstract

The management of rheumatoid arthritis (RA) follows a treat-to-target approach, as recommended by guidelines from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). RA treatment recommendations include an emphasis on frequent disease activity assessments to optimize therapy, recognizing the possibility of timely therapies to slow progression and improve long-term results. The evaluation of joint inflammation, pain, physical function, and clinical indicators is required for comprehensive RA therapy. Current therapeutic goals include achieving low disease activity or remission to enhance the quality of life (QoL) for patients. ACR-endorsed RA disease activity measures, such as the Disease Activity Score in 28 Joints with erythrocyte sedimentation rate or C-reactive protein level, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Scale-II, and Routine Assessment of Patient Index Data 3, are recommended for their precision and sensitivity in supporting treat-to-target strategies. The ACR and EULAR have implemented Boolean-based and index-based remission criteria (SDAI and CDAI, respectively) to evaluate therapeutic effectiveness. The use of these markers regularly aligns with the ACR guidelines, improving adherence to quality indicators in clinical practice and confirming the provision of high-quality RA therapy. This review examines disease activity, function, and QoL measurements in line with the ACR and EULAR guidelines to aid doctors in treating Korean patients with RA.

Keyword

Rheumatoid arthritis; Disease severity; Quality of life

Reference

1. Kim H, Sung YK. 2021; Epidemiology of rheumatoid arthritis in Korea. J Rheum Dis. 28:60–7. DOI: 10.4078/jrd.2021.28.2.60. PMID: 37476013. PMCID: PMC10324889.

2. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021; 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 73:1108–23. DOI: 10.1002/art.41752. PMID: 34101376.

3. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. 2020; EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 79:685–99. DOI: 10.1136/annrheumdis-2019-216655. PMID: 31969328.

4. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2016; 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 68:1–25. DOI: 10.1002/acr.22783. PMID: 26545825.

5. England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, et al. 2019; 2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res (Hoboken). 71:1540–55. DOI: 10.1002/acr.24042. PMID: 31709779. PMCID: PMC6884664.

6. Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, et al. 2018; Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. RMD Open. 4:e000773. DOI: 10.1136/rmdopen-2018-000773. PMID: 30488000. PMCID: PMC6242030.

7. Song GG, Lee YH. 2016; Comparison of disease activity score 28 using c-reactive protein and disease activity score 28 using erythrocyte sedimentation rate in assessing activity and treatment response in rheumatoid arthritis: a meta-analysis. J Rheum Dis. 23:241–9. DOI: 10.4078/jrd.2016.23.4.241.

8. Park SY, Lee H, Cho SK, Choi CB, Sung YK, Bae SC. 2012; Evaluation of disease activity indices in Korean patients with rheumatoid arthritis. Rheumatol Int. 32:545–9. DOI: 10.1007/s00296-011-1798-x. PMID: 21305296.

9. Smolen JS, Aletaha D, Gruben D, Zwillich SH, Krishnaswami S, Mebus C. 2017; Brief report: remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria. Arthritis Rheumatol. 69:728–34. DOI: 10.1002/art.39996. PMID: 27907269. PMCID: PMC5396306.

10. Wong AL, Harker JO, Park GS, Paulus HE. 2004; Longitudinal measurement of RA disease activity in a clinical practice setting: usefulness of the SDAL [abstract]. Arthritis Rheum. 50:S386–7.

11. Fleischmann R, Strand V, Wilkinson B, Kwok K, Bananis E. 2016; Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis. RMD Open. 2:e000232. DOI: 10.1136/rmdopen-2015-000232. PMID: 27175296. PMCID: PMC4860866.

12. Wolfe F, Michaud K, Pincus T. 2005; A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol. 32:2410–5.

13. Seo MR, Kim G, Moon KW, Sung YK, Yoo JJ, Yoon CH, et al. 2021; Quality indicators for evaluating the health care of patients with rheumatoid arthritis: a Korean expert consensus. J Korean Med Sci. 36:e109. DOI: 10.3346/jkms.2021.36.e109. PMID: 33942576. PMCID: PMC8093604.

14. Pincus T, Swearingen CJ, Bergman MJ, Colglazier CL, Kaell AT, Kunath AM, et al. 2010; RAPID3 (routine assessment of patient index data) on an MDHAQ (multidimensional health assessment questionnaire): agreement with DAS28 (disease activity score) and CDAI (clinical disease activity index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken). 62:181–9. DOI: 10.1002/acr.20066. PMID: 20191516.

15. Kim SK, Park SH, Bae J, Son JT, Choe JY. 2014; Performance of routine assessment of patient index data 3 (RAPID3) for assessment of rheumatoid arthritis in clinical practice: differential agreement of RAPID3 according to disease activity categories. Rheumatol Int. 34:1311–8. DOI: 10.1007/s00296-014-3042-y. PMID: 24832679.

16. Bykerk VP, Massarotti EM. 2012; The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford). 51 Suppl 6:vi16–20. DOI: 10.1093/rheumatology/kes281. PMID: 23221582.

17. Megari K. 2013; quality of life in chronic disease patients. Health Psychol Res. 1:e27. DOI: 10.4081/hpr.2013.e27. PMID: 26973912. PMCID: PMC4768563.

18. Patrick DL, Erickson P. Walker SR, Rosser RM, editors. 1993. Assessing health-related quality of life for clinical decision-making. Quality of life assessment: key Issues in the 1990s. Springer;Dordrecht: p. 11–63. DOI: 10.1007/978-94-011-2988-6_2.

19. Wolfe F, Michaud K, Pincus T. 2004; Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum. 50:3296–305. DOI: 10.1002/art.20549. PMID: 15476213.

20. Bae SC, Cook EF, Kim SY. 1998; Psychometric evaluation of a Korean Health Assessment Questionnaire for clinical research. J Rheumatol. 25:1975–9.

21. Pincus T, Sokka T, Kautiainen H. 2005; Further development of a physical function scale on a MDHAQ [corrected] for standard care of patients with rheumatic diseases. J Rheumatol. 32:1432–9.

22. Lee SS, Park MJ, Yoon HJ, Park YW, Park IH, Park KS. 2006; Evaluating the Korean version of the multidimensional health assessment questionnaire in patients with rheumatoid arthritis. Clin Rheumatol. 25:353–7. DOI: 10.1007/s10067-005-0049-5. PMID: 16273310.

23. Wahl E, Gross A, Chernitskiy V, Trupin L, Gensler L, Chaganti K, et al. 2017; Validity and responsiveness of a 10-item patient-reported measure of physical function in a rheumatoid arthritis clinic population. Arthritis Care Res (Hoboken). 69:338–46. DOI: 10.1002/acr.22956. PMID: 27332620. PMCID: PMC6369925.

24. Kang D, Kim Y, Lim J, Yoon J, Kim S, Kang E, et al. 2022; Validation of the Korean version of the patient-reported outcomes measurement information system 29 profile V2.1 among cancer survivors. Cancer Res Treat. 54:10–9. DOI: 10.4143/crt.2020.1200. PMID: 33848414. PMCID: PMC8756127.

25. Kim MH, Cho YS, Uhm WS, Kim S, Bae SC. 2005; Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases. Qual Life Res. 14:1401–6. DOI: 10.1007/s11136-004-5681-z. PMID: 16047514.